Kabra Drugs P/E Ratio
Kabra Drugs (KABRADG) P/E ratio is not applicable — EPS (TTM) ₹-0.99. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
No recent earnings data available.
Current EPS: ₹-0.99
Healthcare Peers with Valid P/E Ratios — KABRADG Comparison
Healthcare sector average P/E 50.07, median 29.4 — KABRADG excluded (negative EPS).
Sector Average PE
50.07
Sector Median PE
29.4
Lowest PE
1.0
Profitable Companies
190
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.0 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.45 | ₹61 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.69 | ₹1,161 | Low |
| Amwill Health Care | AMWILL | 6.34 | ₹65 | Low |
| Brooks Laboratories | BROOKS | 6.6 | ₹137 | Low |
| Mono Pharmacare | MONOPHARMA | 7.1 | ₹21 | Low |
| Shelter Pharma | SHELTER | 7.4 | ₹54 | Low |
| Medicamen Organics | MEDIORG | 7.51 | ₹32 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹66 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Kabra Drugs stock price NSE.
- Browse KABRADG annual financials for revenue, profit, balance sheet and cash flow data.
- Analyse Kabra Drugs ownership structure to track promoter, FII and institutional holdings.